Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved

Webinar

Watch on-demand

Join cardiologist Lars Rydén, endocrinologist Alice Cheng, and primary care practitioner Kevin Saunders who discuss the diagnosis and management of people with type 2 diabetes and shortness of breath in primary care, and how the positive findings of EMPEROR-Preserved will now shape the care of these patients. Watch now

Keep up with the latest news on HFpEF

20-12-2022 | Dapagliflozin | News

Dapagliflozin on way to EC approval for all heart failure

Click through to read more on this announcement

06-12-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.

18-11-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

02-09-2022 | Dapagliflozin | News

DELIVER results round-up: Frailty, AF, recent hospitalization, and more

31-08-2022 | Heart failure | News

‘Strikingly consistent’ evidence for SGLT2 inhibitor benefits across the spectrum of heart failure

27-08-2022 | Dapagliflozin | News

Dapagliflozin DELIVERs improved HFpEF outcomes

01-03-2022 | Empagliflozin | News

Empagliflozin indication extended to all heart failure in USA

28-02-2022 | Canagliflozin | News

Virtual CHIEF-HF trial supports canagliflozin in heart failure

28-02-2022 | Empagliflozin | News

EMPULSE shows empagliflozin benefit in acute heart failure

Interviews on heart failure

01-11-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: The implications for primary care

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.

02-03-2022 | Empagliflozin | Video

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.

Image Credits